

Adam C. Morse, D.O.

Adam C. Morse, D.O.

Florida Orthopaedic Institute
13020 Telecom Pkwy N
Temple Terrace, FL 33637
(813) 978-9700

Educational Background

University

University of Southern California
Los Angeles, CA
1988

Medical School

Western University of the Health
Sciences
Pomona, CA
1994

Internship

Ohio University
Dayton, OH
1995

Residency

Michigan State University, Garden
City Osteopathic Hospital
Garden City, MI
1999

Fellowship

Sports Medicine Orthopedics
Florida Orthopaedic Institute
Tampa, FL
2000

Academic, Hospital And Business Appointments

- Florida Orthopaedic Institute, Division of Sports Medicine, 2000-Present
- Past Clinical Instructor, University of South Florida
- Past Clinical Instructor, Michigan State University

Board Certifications

- American Osteopathic Board of Orthopedic Surgery

Sports Medicine Affiliations

Currently Serving

- Carrollwood Day School, Team Physician
- VSI Flames Pro Soccer, Team Physician
- Tampa Bay Buccaneers, Team Physician
- Sickles High School, Team Physician

Has also served as

- University of South Florida, Team Physician
- University of Tampa, Assistant Team Physician
- Tampa Bay Storm, Team Physician
- Chamberlain H.S., Team Physician
- St. Leo University, Team Physician
- Tampa Bay Lightning, Assistant Team Physician, 1999-2001
- Rowdies FC Tampa Bay, Team Physician

Research Experience

- University of Southern California School of Medicine, Department of Medicine, Division of Oncology, June 1988-July 1990
 - Examined the response of cloned T-cells to a combination of allogeneic melanoma lysates, interleukins 1-6, and an adjuvant. Responsible for production of the new "Theraccine" melanoma therapeutic vaccine for clinical trials.
- Merck & Co., Inc.
 - Primary Investigator for a three-stage study – An Open-label, Large Simple Usual Care Study of the Effect of adding Rofecoxib 50mg to a Regimen of Selected Opioid Analgesic PRN in Patients Undergoing Selected Outpatient Surgical Knee Arthroscopy Procedures.
- AAI International
 - Primary Investigator – Study of the safety and efficacy of Diclofenac prosorb soft gel 25mg or 50mg in the treatment of Arthroscopic knee surgery A Phase III randomizes, multi-center parallel group double-masked, placebo controlled
- Stryker Orthopaedics
 - Primary Investigator, Dr. Seth Gasser
 - Sub-Investigator, Dr. Adam Morse
 - "Resorption and Remodeling of HA-PLLA Interference Screw in Patients Up to 9 years Post Anterior Cruciate Ligament Reconstruction"
 - Primary, To compare the bone density in Hounsfield units in the tibial and femoral tunnel tracts mid-screw CT slice of subjects at 84, 96, and 108 months after reconstruction and compare this with muscle and surrounding cancellous bone density.
 - Secondary, To examine the ossification rates of tibial and femoral screws. To look at rates of sclerosis along the screw tracts. To score the osteointegration according to the rating system proposed by Barber and Dockery.